Cite
HARVARD Citation
Straus, D. et al. (2021). Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet. 8 (6), pp. e410-e421. [Online].